CD274 and renal cell carcinoma: We further identified that high expression of these 6 genes in pretreatment RCC tumors associated with a favorable prognosis in a combined cohort of 428 patients that treated with either atezolizumab or durvalumab anti-PDL1 immunotherapy 8 (Fig. 4C).